<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30144023</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1097-0215</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>143</Volume>                    <Issue>11</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Dec</Month>                        <Day>01</Day>                    </PubDate>                </JournalIssue>                <Title>International journal of cancer</Title>                <ISOAbbreviation>Int. J. Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>The expression of LINE1-MET chimeric transcript identifies a subgroup of aggressive breast cancers.</ArticleTitle>            <Pagination>                <MedlinePgn>2838-2848</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/ijc.31831</ELocationID>            <Abstract>                <AbstractText>Demethylation of the long interspersed nuclear element (LINE-1; L1) antisense promoter can result in transcription of neighboring sequences as for the L1-MET transcript produced by the L1 placed in the second intron of MET. To define the role of L1-MET, we investigated the sequence and the transcription of L1-MET in vitro models and heterogeneous breast cancers, previously reported to show other L1-derived transcripts. L1-MET expressing cell lines were initially identified in silico and investigated for L1-MET promoter methylation, cDNA sequence and cell fraction mRNA. The transcriptional level of L1-MET and MET were then evaluated in breast specimens, including 9 cancer cell lines, 41 carcinomas of different subtypes, and 11 normal tissues. In addition to a L1-MET transcript ending at MET exon 21, six novel L1-MET splice variants were identified. Normal breast tissues were negative for the L1-MET expression, whereas the triple-negative breast cancer (TNBC) and the high-grade carcinomas were enriched with the L1-MET mRNA (p = 0.005 and p = 0.018, respectively). In cancer cells and tissues the L1-MET expression was associated with its promoter hypomethylation (ρ = -0.8 and -0.9, respectively). No correlation was found between L1-MET and MET mRNA although L1-MET expressing tumors with higher L1-MET/MET ratio were negative for the MET protein expression (p = 0.006). Besides providing the first identification and detailed description of L1-MET in breast cancer, we clearly demonstrate that higher levels of this transcript specifically recognize a subset of more aggressive carcinomas, mainly TNBC. We suggest the possible evaluation of L1-MET in the challenging diagnosis of early TNBCs.</AbstractText>                <CopyrightInformation>© 2018 UICC.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Miglio</LastName>                    <ForeName>Umberto</ForeName>                    <Initials>U</Initials>                    <AffiliationInfo>                        <Affiliation>Unit of Pathology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Berrino</LastName>                    <ForeName>Enrico</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Unit of Pathology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Panero</LastName>                    <ForeName>Mara</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Unit of Pathology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ferrero</LastName>                    <ForeName>Giulio</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Computer Science, University of Turin, Turin, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Coscujuela Tarrero</LastName>                    <ForeName>Lucia</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Miano</LastName>                    <ForeName>Valentina</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dell'Aglio</LastName>                    <ForeName>Carmine</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Unit of Pathology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sarotto</LastName>                    <ForeName>Ivana</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Unit of Pathology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Annaratone</LastName>                    <ForeName>Laura</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Sciences, University of Turin, Turin, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Marchiò</LastName>                    <ForeName>Caterina</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Unit of Pathology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medical Sciences, University of Turin, Turin, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Comoglio</LastName>                    <ForeName>Paolo M</ForeName>                    <Initials>PM</Initials>                    <AffiliationInfo>                        <Affiliation>Molecular Therapeutics and Exploratory Research Laboratory, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>De Bortoli</LastName>                    <ForeName>Michele</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pasini</LastName>                    <ForeName>Barbara</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Sciences, University of Turin, Turin, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Venesio</LastName>                    <ForeName>Tiziana</ForeName>                    <Initials>T</Initials>                    <Identifier Source="ORCID">https://orcid.org/0000-0002-9035-056X</Identifier>                    <AffiliationInfo>                        <Affiliation>Unit of Pathology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sapino</LastName>                    <ForeName>Anna</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Unit of Pathology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medical Sciences, University of Turin, Turin, Italy.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <Agency>Fondazione Umberto Veronesi Post-Doctoral Fellowship (VM and LA)</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>15600 (MDB)</GrantID>                    <Agency>AIRC IG</Agency>                    <Country/>                </Grant>                <Grant>                    <Agency>Italian Ministry of Health, Ricerca Corrente 2017 (AS)</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>9970 (PMC; AS)</GrantID>                    <Agency>AIRC 5xMille MCO Extension Program</Agency>                    <Country/>                </Grant>                <Grant>                    <Agency>FPRC 5xMille Ministero Salute 2014 (PMC; AS)</Agency>                    <Country/>                </Grant>                <Grant>                    <Agency>FPRC 5xMille Ministero Salute 2011 (PMC)</Agency>                    <Country/>                </Grant>                <Grant>                    <Agency>FPRC 5xMille Ministero Salute 2013 (AS)</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>04</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Int J Cancer</MedlineTA>            <NlmUniqueID>0042124</NlmUniqueID>            <ISSNLinking>0020-7136</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">L1-MET</Keyword>            <Keyword MajorTopicYN="N">LINE-1</Keyword>            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">chimeric transcript</Keyword>            <Keyword MajorTopicYN="N">triple negative breast cancer (TNBC)</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>17</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>15</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30144023</ArticleId>            <ArticleId IdType="doi">10.1002/ijc.31831</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>